Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JK0A | ISIN: US26745T1016 | Ticker:
NASDAQ
16.11.26 | 16:43
0,335 US-Dollar
+3,59 % +0,012
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DYADIC INTERNATIONAL INC Chart 1 Jahr
5-Tage-Chart
DYADIC INTERNATIONAL INC 5-Tage-Chart

Aktuelle News zur DYADIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrDYADIC INTERNATIONAL INC - 10-Q, Quarterly Report-
FrDYADIC INTERNATIONAL INC - 8-K, Current Report-
DYADIC Aktie jetzt für 0€ handeln
DoDyadic International GAAP EPS of -$0.04 in-line, revenue of $0.45M misses by $0.98M1
DoDyadic International, Inc.: Dyadic's C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations366Preclinical Studies Will Compare C1-Produced Antibodies to Their CHO-Produced CounterpartsJUPITER, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:...
► Artikel lesen
25.09.DYADIC INTERNATIONAL INC - 8-K, Current Report2
11.09.DYADIC INTERNATIONAL INC - S-1, General form for registration of securities1
26.08.Dyadic: Nach kommerzieller Neuausrichtung rückt positiver Cashflow in den Fokus1
13.08.Dyadic International secures $2.9M via registered direct offering and concurrent warrant private placement1
13.08.Dyadic signals 40% transferrin cost reduction as it pursues non-dilutive capital amid going concern disclosure3
12.08.Dyadic International GAAP EPS of -$0.06 misses by $0.03, revenue of $0.96M misses by $0.67M2
12.08.Dyadic reports Q2 loss amid commercialization efforts3
12.08.DYADIC INTERNATIONAL INC - 8-K, Current Report2
12.08.DYADIC INTERNATIONAL INC - 10-Q, Quarterly Report2
12.08.Dyadic International, Inc.: Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas2.170JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology...
► Artikel lesen
05.08.Dyadic erweitert sein Portfolio an tierfreien Milchprodukten für den kommerziellen Markt durch eine neue strategische Entwicklungsvereinbarung2
04.08.Dyadic International, Inc.: Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement448New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategyJUPITER, Fla., Aug. 04, 2026...
► Artikel lesen
28.07.Dyadic International, Inc.: Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days1.390Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena ("FBS") and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand...
► Artikel lesen
24.07.DYADIC INTERNATIONAL INC - 8-K, Current Report2
24.07.Dyadic regains compliance with Nasdaq listing requirements4
24.07.Dyadic International, Inc.: Dyadic Announces Continued Listing on the Nasdaq Capital Market474JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant...
► Artikel lesen
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1